Stay updated with breaking news from Junshi Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Interim results to be presented September 17 at the European Society for Medical Oncology (ESMO) Congress 2021 –
- Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone - - Data support the use of toripalimab with chemotherapy as first-line
1st line nasopharyngeal indication and 2nd/3rd line indications to be concurrently submitted 3Q 2021 in the toripalimab BLA SHANGHAI, China and REDWOOD CITY, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Shanghai
Investegate announcements from Junshi Biosciences, Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma
Press release content from Globe Newswire. The AP news staff was not involved in its creation.